Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.53 |
| ▸ | PARP1 | P09874 | 7/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362890 | 1.00 | PARP10 (0.53) | PARP10PARP1PARP11CDK2ACHE | |
| SCHEMBL17141660 | 0.81 | CLK4 (0.46) | PARP10PARP1PARP11GRM5 | |
| SCHEMBL28032373 | 0.81 | PARP10 (0.51) | PARP10PARP1PARP11CDK2ACHE | |
| SCHEMBL23951998 | 0.77 | PARP10 (0.56) | PARP10PARP1PARP11CDK2ACHE | |
| SCHEMBL1725137 | 0.77 | PARP10 (0.51) | PARP10PARP1PARP11RAF1MAPK1 | |
| SCHEMBL30197872 | 0.77 | PARP10 (0.56) | PARP10PARP1PARP11CDK2ACHE | |
| SCHEMBL32669451 | 0.77 | PARP10 (0.44) | PARP10PARP1PARP11CDK2ACHE | |
| SCHEMBL4816505 | 0.76 | SRD5A1 (0.36) | PARP10PARP1PARP11RAF1MAPK1 | |
| SCHEMBL29776117 | 0.76 | SRD5A1 (0.36) | PARP10PARP1PARP11RAF1MAPK1 | |
| SCHEMBL21333626 | 0.73 | FABP6 (0.48) | PARP10PARP1PARP11RAF1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294742-B | Fused ring ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
| EP-3303318-A1 | BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016198400-A1 | BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | PARP10 1687/4885PARP1 1553/4885PARP11 2519/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | PARP10 3857/4885PARP1 2142/4885PARP11 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.